Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Metadata
Title
Reduced telomere DNA content is correlated with genomic instability and metastasis in invasive human breast carcinoma
Authors
Jeffrey K. Griffith
Jennifer E. Bryant
Colleen A. Fordyce
Frank D. Gilliland
Nancy E. Joste
Robert K. Moyzis
Publication date
01-03-1999
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 1/1999
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1006128228761

Other articles of this Issue 1/1999

Breast Cancer Research and Treatment 1/1999 Go to the issue

OriginalPaper

Risk factors for a decline in upper body function following treatment for early stage breast cancer

OriginalPaper

IGF-I and retinoic acid regulate the distribution pattern of IGFBPs synthesized by the canine mammary tumor cell line CMT-U335

OriginalPaper

Instructions for authors

OriginalPaper

Analyzing prognostic factors in breast cancer using a multistate model

OriginalPaper

Tumor flow in malignant breast tumors measured by Doppler ultrasound: an independent predictor of survival

OriginalPaper

Synergistic cooperation between c-Myc and Bcl-2 in lymph node progression of T1 human breast carcinomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits